Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: A multicenter experience

Basit Öğe Kaydı
dc.authoridKAYA, Emin/0000-0001-8605-8497
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X;
dc.authorwosidUlas, Turgay TU/A-6050-2018
dc.authorwosidKAYA, Emin/W-2951-2017
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidYonal-Hindilerden, Ipek/KOC-6710-2024
dc.contributor.authorBatgi, Hikmettullah
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorKuku, Irfan
dc.contributor.authorKurtoglu, Erdal
dc.contributor.authorHindilerden, Ipek Yonal
dc.contributor.authorKaya, Emin
dc.date.accessioned2024-08-04T20:50:34Z
dc.date.available2024-08-04T20:50:34Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground and objectives: Extracorporeal photopheresis (ECP) is one of the second-line treatment strategies in steroid-refractory acute graft-versus-host disease (aGvHD). We aimed to share our multicenter experience using ECP in our steroid-refractory aGvHD patients. Materials and methods: A retrospective observational series of 75 aGvHD patients from 4 transplant centers were analyzed. All ECP procedures were performed with the off-line system. All patients received ECP as second-line therapy. Results: 74.7 % of aGvHD patients were grade 3 or 4. The overall response rate was 42.7 % (32/75) in aGvHD including 17 complete responses (22.7 %). Median follow-up was 6 months (range, 1-68). Median overall survival (OS) was 5 months for non-responders and 68 months for responders (p < 0.001). Twenty-seven (36 %) patients are alive, and 48 (64 %) patients have died. Conclusions: Early initiated ECP could be an effective treatment alternative in patients with steroid-refractory aGvHD.en_US
dc.identifier.doi10.1016/j.transci.2021.103242
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue5en_US
dc.identifier.pmid34420882en_US
dc.identifier.scopus2-s2.0-85113149369en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2021.103242
dc.identifier.urihttps://hdl.handle.net/11616/100147
dc.identifier.volume60en_US
dc.identifier.wosWOS:000697004600003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectExtracorporeal photopheresisen_US
dc.subjectAllogeneic stem cell transplantationen_US
dc.subjectAcute graft versus host diseaseen_US
dc.titleExtracorporeal photopheresis in the treatment of acute graft-versus-host disease: A multicenter experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu